Skip to main content

Table 2 Factors affecting CAMPHOR domains

From: Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study

 

Symptoms

p

Activities

p

Quality of life

p

Age

      

  < 60 years

6.5

 

6.5

 

3.0

 

  ≥ 60 years

4.5

0.504

9.0

0.634

4.0

0.763

Gender

      

 Male

5.5

 

9.0

 

4.0

 

 Female

5.0

0.454

5.0

0.118

2.5

0.289

Time since diagnosis

      

  < 5 years

5.0

 

9.0

 

3.0

 

  ≥ 5 years

6.0

0.691

6.0

0.351

4.0

0.917

Combination therapy

      

 Yes

6.0

 

9.0

 

2.0

 

 No

4.0

0.784

7.0

0.974

4.0

0.508

Line of treatment

      

 First line

5.0

 

6.5

 

4.0

 

 Second or later

6.5

0.893

9.0

0.800

2.5

0.399

Number of concomitant drugs

      

  < 7 drugs

4.0

 

6.0

 

3.0

 

   ≥ 7 drugs

7.5

0.040

9.5

0.135

4.0

0.078

Number of comorbidities

      

  < 3

4.0

 

6.0

 

3.0

 

   ≥ 3

8.0

0.155

10.0

0.170

7.0

0.085

Borg dyspnea

      

  < 4

6.0

 

6.0

 

6.0

 

  ≥ 4

8.0

0.262

8.0

0.313

8.0

0.350

At least 1 emergency visit in the last 12 months

      

 No

4.0

 

6.0

 

3.0

 

 Yes

7.0

0.098

10.0

0.214

7.0

0.045

At least 1 hospitalization in the last 12 months

      

 No

4.0

 

6.0

 

3.0

 

 Yes

7.0

0.020

10.0

0.063

7.0

0.040